CN Patent

CN113248500B — 氮杂吲哚嘧啶胺杂环化合物及其制备方法和应用

Assigned to China Pharmaceutical University · Expires 2021-10-19 · 5y expired

What this patent protects

本发明公开了一种氮杂吲哚嘧啶胺杂环化合物及其制备方法和应用，所述化合物如式（S）所示。本发明的化合物能抑制癌症的恶性增殖，治疗效果好、毒性低，具有良好药物代谢特性、不易产生耐药性，可用于制备治疗癌症或肿瘤相关疾病药物，所述癌症或肿瘤相关疾病包括多发性骨髓瘤、白血病、乳腺癌、前列腺癌、肺癌、肝癌、胃癌、骨癌、脑癌、头颈癌、肠癌、胰腺癌、膀胱癌、睾丸癌、卵巢癌以及子宫内膜癌。

USPTO Abstract

本发明公开了一种氮杂吲哚嘧啶胺杂环化合物及其制备方法和应用，所述化合物如式（S）所示。本发明的化合物能抑制癌症的恶性增殖，治疗效果好、毒性低，具有良好药物代谢特性、不易产生耐药性，可用于制备治疗癌症或肿瘤相关疾病药物，所述癌症或肿瘤相关疾病包括多发性骨髓瘤、白血病、乳腺癌、前列腺癌、肺癌、肝癌、胃癌、骨癌、脑癌、头颈癌、肠癌、胰腺癌、膀胱癌、睾丸癌、卵巢癌以及子宫内膜癌。

Drugs covered by this patent

Patent Metadata

Patent number
CN113248500B
Jurisdiction
CN
Classification
—
Expires
2021-10-19
Drug substance claim
No
Drug product claim
No
Assignee
China Pharmaceutical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.